CD14 and amyotrophic lateral sclerosis: This finding is in line with the emerging favorable safety profile associated with clinical trials of CD14 blockade in patients with amyotrophic lateral sclerosis (NCT04309604, NCT03487263)29 and COVID-19 pneumonia (NCT04391309).31